KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

NovoCure (NVCR) Leases (2019 - 2025)

NovoCure (NVCR) has disclosed Leases for 7 consecutive years, with $47.3 million as the latest value for Q4 2025.

  • Quarterly Leases rose 74.51% to $47.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.3 million through Dec 2025, up 74.51% year-over-year, with the annual reading at $47.3 million for FY2025, 74.51% up from the prior year.
  • Leases hit $47.3 million in Q4 2025 for NovoCure, down from $48.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $48.5 million in Q1 2025 to a low of $16.5 million in Q3 2021.
  • Historically, Leases has averaged $28.8 million across 5 years, with a median of $26.7 million in 2023.
  • Biggest five-year swings in Leases: decreased 22.15% in 2024 and later soared 74.51% in 2025.
  • Year by year, Leases stood at $18.3 million in 2021, then increased by 29.17% to $23.6 million in 2022, then soared by 47.63% to $34.8 million in 2023, then decreased by 22.15% to $27.1 million in 2024, then skyrocketed by 74.51% to $47.3 million in 2025.
  • Business Quant data shows Leases for NVCR at $47.3 million in Q4 2025, $48.4 million in Q3 2025, and $48.1 million in Q2 2025.